Azitra Inc. (AZTR)
0.28
-0.01 (-4.11%)
At close: Apr 15, 2025, 3:59 PM
0.29
2.41%
After-hours: Apr 15, 2025, 06:06 PM EDT
-4.11% (1D)
| Bid | 0.28 |
| Market Cap | 4.2M |
| Revenue (ttm) | 7.5M |
| Net Income (ttm) | -8.97M |
| EPS (ttm) | -71.1 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.32 |
| Analyst | n/a |
| Ask | 0.29 |
| Volume | 328,242 |
| Avg. Volume (20D) | 6,202,234 |
| Open | 0.30 |
| Previous Close | 0.29 |
| Day's Range | 0.28 - 0.32 |
| 52-Week Range | 0.23 - 12.00 |
| Beta | -1.82 |
About AZTR
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergo...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 20, 2023
Employees 12
Stock Exchange AMEX
Ticker Symbol AZTR
Website https://azitrainc.com
2 months ago
-6.17%
Azitra shares are trading lower after the company ...
Unlock content with
Pro Subscription
3 months ago
-39.03%
Azitra shares are trading lower after the company announced the pricing of a $1.5 million public offering.
6 months ago · businesswire.com
Azitra to Participate in the 2024 Maxim Healthcare Virtual SummitBRANFORD, Conn.--(BUSINESS WIRE)---- $AZTR #Maxim--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, ...